Ignite Creation Date:
2025-12-24 @ 2:02 PM
Ignite Modification Date:
2026-05-09 @ 4:13 PM
Study NCT ID:
NCT02799095
Status:
COMPLETED
Last Update Posted:
2025-05-21
First Post:
2016-06-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Sponsor:
Mural Oncology, Inc
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Solid Tumors | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Immunotherapy | View |
| None | IL-2 | View |
| None | Interleukin-2 | View |
| None | Solid tumors | View |
| None | Melanoma | View |
| None | Renal cell carcinoma | View |
| None | Non-small-cell lung cancer | View |
| None | Squamous cell carcinoma of the head and neck | View |
| None | in combination with pembrolizumab | View |